Supramolecular Heterodimer Peptides Assembly for Nanoparticles Functionalization.


Journal

Advanced healthcare materials
ISSN: 2192-2659
Titre abrégé: Adv Healthc Mater
Pays: Germany
ID NLM: 101581613

Informations de publication

Date de publication:
05 Mar 2024
Historique:
revised: 22 01 2024
received: 01 12 2023
medline: 6 3 2024
pubmed: 6 3 2024
entrez: 6 3 2024
Statut: aheadofprint

Résumé

Nanoparticle (NP) surface functionalization with proteins, including monoclonal antibodies (mAbs), mAb fragments, and various peptides, has emerged as a promising strategy to enhance tumor targeting specificity and immune cell interaction. However, these methods often rely on complex chemistry and suffer from batch-dependent outcomes, primarily due to limited control over the protein orientation and quantity on NP surfaces. To address these challenges, we present a novel approach based on the supramolecular assembly of two peptides to create a heterotetramer displaying V

Identifiants

pubmed: 38444191
doi: 10.1002/adhm.202304250
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e2304250

Informations de copyright

This article is protected by copyright. All rights reserved.

Auteurs

C Mathieu (C)

Institut de Cancérologie Strasbourg Europe, Strasbourg, 67000, France.
Strasbourg Drug Discovery and Development Institute (IMS), Strasbourg, 67000, France.
Equipe labellisée ligue contre le cancer, 26 Rue d'Ulm, Paris, 75005, France.

S Ghosh (S)

Institut de Cancérologie Strasbourg Europe, Strasbourg, 67000, France.
Strasbourg Drug Discovery and Development Institute (IMS), Strasbourg, 67000, France.
Equipe labellisée ligue contre le cancer, 26 Rue d'Ulm, Paris, 75005, France.

J Draussin (J)

Institut de Cancérologie Strasbourg Europe, Strasbourg, 67000, France.
Strasbourg Drug Discovery and Development Institute (IMS), Strasbourg, 67000, France.
Equipe labellisée ligue contre le cancer, 26 Rue d'Ulm, Paris, 75005, France.

A Gasser (A)

Institut de Cancérologie Strasbourg Europe, Strasbourg, 67000, France.
Strasbourg Drug Discovery and Development Institute (IMS), Strasbourg, 67000, France.
Equipe labellisée ligue contre le cancer, 26 Rue d'Ulm, Paris, 75005, France.

G Jacquot (G)

Institut de Cancérologie Strasbourg Europe, Strasbourg, 67000, France.
Strasbourg Drug Discovery and Development Institute (IMS), Strasbourg, 67000, France.
Equipe labellisée ligue contre le cancer, 26 Rue d'Ulm, Paris, 75005, France.

M Banerjee (M)

Institut de Cancérologie Strasbourg Europe, Strasbourg, 67000, France.
Strasbourg Drug Discovery and Development Institute (IMS), Strasbourg, 67000, France.
Equipe labellisée ligue contre le cancer, 26 Rue d'Ulm, Paris, 75005, France.

T Gupta (T)

Laboratoire de Bioimagerie et Pathologies, Université de Strasbourg, UMR 7021 CNRS, Illkirch, 67401, France.

M Schmutz (M)

Université de Strasbourg, CNRS, Institut Charles Sadron, UPR 22, Strasbourg, 67034, France.

C Mirjolet (C)

Radiation Oncology Department, Preclinical Radiation Therapy and Radiobiology Unit, Centre Georges-François Leclerc, Unicancer, Dijon, France.
TIReCS team, INSERM UMR 1231, Dijon, France.

O Tillement (O)

Institut Lumière-Matière, UMR 5306, Université Claude Bernard Lyon1-CNRS, Villeurbanne Cedex, France.

F Lux (F)

Institut Lumière-Matière, UMR 5306, Université Claude Bernard Lyon1-CNRS, Villeurbanne Cedex, France.
Institut Universitaire de France (IUF), Paris, 75231, France.

A Klymchenko (A)

Laboratoire de Bioimagerie et Pathologies, Université de Strasbourg, UMR 7021 CNRS, Illkirch, 67401, France.

M Donzeau (M)

Institut de génétique et de biologie moléculaire et cellulaire, Illkirch, 67404, France.

X Pivot (X)

Institut de Cancérologie Strasbourg Europe, Strasbourg, 67000, France.
Strasbourg Drug Discovery and Development Institute (IMS), Strasbourg, 67000, France.
Equipe labellisée ligue contre le cancer, 26 Rue d'Ulm, Paris, 75005, France.

S Harlepp (S)

Institut de Cancérologie Strasbourg Europe, Strasbourg, 67000, France.
Strasbourg Drug Discovery and Development Institute (IMS), Strasbourg, 67000, France.
Equipe labellisée ligue contre le cancer, 26 Rue d'Ulm, Paris, 75005, France.

A Detappe (A)

Institut de Cancérologie Strasbourg Europe, Strasbourg, 67000, France.
Strasbourg Drug Discovery and Development Institute (IMS), Strasbourg, 67000, France.
Equipe labellisée ligue contre le cancer, 26 Rue d'Ulm, Paris, 75005, France.

Classifications MeSH